Pilot study of the combination of melphalan, carboplatin and etoposide as a conditioning regimen for relapsed lymphoma patients.
del Giglio
A
A
ABC Foundation School of Medicine, São Paulo, Brazil. sandrabr@netpoint.com.br
Costa
L J
LJ
Pinczowski
H
H
Varella
P C
PC
Luzzi
J R
JR
Neves
P
P
Mota
A
A
Boente
P
P
Sampaio
C
C
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D010865:Pilot Projects; D012008:Recurrence; D019172:Transplantation Conditioning
D000970:Antineoplastic Agents; D005047:Etoposide; D016190:Carboplatin; D008558:Melphalan